November 20th 2024
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 16, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Power adjustment at slit lamp: Pseudophakic light-adjustable IOL set to enter clinical trials
February 1st 2003Orlando-A new light-adjustable IOL (LAL) has been designed that will allow for noninvasive correction of residual refractive errors present after cataract surgery, said Daniel M. Schwartz, MD, during the refractive surgery subspecialty day meeting prior to the annual meeting of the American Academy of Ophthalmology. Researchers are ready to begin testing the LAL in clinical trials, he added.
Read More
Dual function laser system is big boon to anterior segment surgeons
January 15th 2003The Selecta Duet (Lumenis), a new dual-purpose laser system, brings anterior segment surgeons a cost-effective and space-saving solution for treating both glaucoma patients undergoing selective laser trabeculoplasty (SLT) and pseudophakic patients in need of Nd:YAG laser capsulotomy for secondary cataract.
Read More
New indication: FDA clears multi-purpose disinfecting solution
January 15th 2003Fort Worth, TX-Alcon has received FDA clearance for its Opti-Free Express Multi-Purpose Disinfecting Solution "no-rub" formula for use with silicone hydrogel lenses. The indication has been added to the product's carton, label, and package insert.
Read More
Inaugural meeting: Symposium to offer seminars in three areas
January 15th 2003Orlando-The Contact Lens and Eyecare Symposium (CLES) will offer more than 130 hours of accredited continuing education courses from which to choose during the group's inaugural meeting, Jan. 22 to 26 at Disney's Coronado Springs Resort in Orlando.
Read More
New strategies needed for long-term filtering bleb survival
December 1st 2002Newark, NJ-Multimodal therapy, close surveillance with prompt intervention for early signs of failure, and long-term suppression of fibroblastic activity may help improve long-term success rates of glaucoma filtering surgery, said Paul J. Lama, MD.
Read More
CMV retinitis treatment responding to changing HIV therapy
December 1st 2002Editor's Note: HIV/AIDS continues to be a major health problem, not only in the developing world, but in North America and Europe as well. Although the incidence of ocular complications of HIV/AIDS has decreased dramatically since the introduction of highly active anti-retroviral therapy (HAART), the prevalence of HIV positivity continues toincrease, particularly among heterosexual women and minorities.
Read More
Clinicians take heed with new glaucoma procedures
November 15th 2002Los Angeles-Considering the limited availability of published randomized trials, glaucoma surgeons should remain skeptical about the safety and efficacy of viscocanalostomy and deep sclerectomy with collagen wick, said Donald S. Minckler, MD.
Read More
Creation of retinochoroidal anastomosis may help those with CRVO
November 1st 2002Mexico City-Surgical treatment of central retinal vein occlusion (CRVO) by the creation of retinochoroidal anastomosis (RCA) may become an effective therapy for some patients with CRVO, according to Hugo Quiroz-Mercado, MD.
Read More
Posterior chamber PRL corrects moderate to high hyperopia
November 1st 2002Rockville Centre, NY-Implantation of a posterior chamber phakic refractive lens (PRL) (Medennium phakic refractive lens, CIBA Vision, Duluth, GA) demonstrated positive visual outcomes in the treatment of high hyperopia, according to Alexander Hatsis, MD, who presented the results of the FDA phase II trial.
Read More
Injecting botulinum toxin A in frontalis may result in ptosis
October 15th 2002New York-Eyelid ptosis following botulinum toxin A (Botox, Allergan) therapy is directly related to using frontalis injection, though other investigators have not linked the characteristic droopiness to that approach, said Michael Kane, MD.
Read More
Vitrectomy may help manage complex, refractory glaucoma
October 15th 2002The management of refractory and complex glaucoma is a challenging and often humbling undertaking. These difficult-to-treat glaucomas include neovascular, traumatic, uveitic, secondary angle closure, postsurgical, and refractory open-angle glaucoma (OAG).
Read More
PCO incidence may decline using photolysis system
October 15th 2002New York-The incidence of posterior capsule opacification (PCO) was found to be significantly lower following cataract extraction with the Nd:YAG laser (Dodick photolysis system, ARC Laser Corp.) than with conventional phaco, according to a study performed at the Manhattan Eye, Ear, and Throat Hospital (MEETH), New York.
Read More
Polishing anterior capsule may increase incidence of PCO
October 15th 2002Los Angeles-Polishing the anterior capsule after phacoemulsification and lens implantation does not appear to reduce the incidence of posterior capsular opacification (PCO). In fact, substantially more eyes that underwent this procedure after cataract surgery needed posterior capsulotomy, a startling finding reported by Kevin M. Miller, MD.
Read More
IOL technology mimics 53-year-old crystalline lens
October 15th 2002Jackson, MI-The new AcrySof Natural IOL (Model SB30AL, Alcon, Fort Worth, TX), which has a light transmission spectrum similar to that of a 53-year-old human crystalline lens, is the first of its kind that has become commercially available. It effectively filters blue light between 400 and 500 nm and preserves contrast sensitivity and color perception, according to Paul Ernest, MD.
Read More
Ophthalmic innovations abound at AAO exhibits in Orlando
October 1st 2002All eyes are focused on Orlando for this year's meeting of the American Academy of Ophthalmology (AAO), Oct. 20 to 23. More than 500 exhibitors will showcase the latest ophthalmic technology in Halls A and B (Level 2) of the Orange County Convention Center.
Read More
Sandwich technique prevents capsular bag opacification
October 1st 2002Salt Lake City-A "sandwich-like" pattern of capsular attachment of a new one-piece hydrophobic acrylic IOL (AcrySof SA30AL, Alcon, Fort Worth, TX) appears to prohibit epithelial ingrowth, according to Liliana Werner, MD, PhD.
Read More
Enhance the face with implants as well as injectables
October 1st 2002Tampa-Direct incision, the placement of autologous tissue grafts, and now the use of expanded polytetrafluoroethylene, or ePTFE, are options for improving facial subunits. While communication between the doctor and patient is important in all cases to determine which option is best, it is particularly useful with ePTFE (SoftForm) implants. The key to patient happiness is patient selection.
Read More
Commitment to R&D strengthens Allergan product pipeline
October 1st 2002Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Read More
Minimal PCO, inflammation seen with single-piece acrylic IOLs
October 1st 2002Baltimore-The AcrySof single-piece acrylic IOLs (Alcon, Fort Worth, TX) provide good refractive correction, excellent stability, and a low incidence of posterior capsular opacification (PCO), said Richard A. Adler, MD.
Read More
Two-piece anterior chamber IOL offers hope for myopia
October 1st 2002New York-An anterior chamber phakic IOL for the treatment of high myopia combats the four major problems facing anterior chamber lenses, according to cataract sur-geon Charles D. Kelman, MD, who described the advantages of his invention.
Read More
Myopia cases on rise: 30-day lenses might offer alternative to LASIK
September 15th 2002Sydney, Australia-A rapid increase in the occurrence of myopia and an aging world population means 70% of the world will require vision correction by year 2020, according to a study by the Cooperative Research Centre for Eye Research and Technology.
Read More